摘要 |
<p>The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.</p> |
申请人 |
ALCON, INC.;HELLBERG, MARK, R.;FLEENOR, DEBRA, L.;SHEPARD, ALLAN;PANG, IOK-HOU |
发明人 |
HELLBERG, MARK, R.;FLEENOR, DEBRA, L.;SHEPARD, ALLAN;PANG, IOK-HOU |